Article in American journal of physiology. Lung cellular and molecular physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors.
Liang FanDepartment of Cellular and Molecular Biology, Texas Lung Injury Institute, The University of Texas Health Science Center at Tyler, Tyler, Texas, United States.
Rashmi S ShettyDepartment of Cellular and Molecular Biology, Texas Lung Injury Institute, The University of Texas Health Science Center at Tyler, Tyler, Texas, United States.
Huy Minh DaoMolecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, Austin, Texas, United States.ORCID 0000-0002-8521-001X
Akarsha BalnadupeteDepartment of Cellular and Molecular Biology, Texas Lung Injury Institute, The University of Texas Health Science Center at Tyler, Tyler, Texas, United States.ORCID 0000-0001-8850-6396
Bharath SomasundramDepartment of Cellular and Molecular Biology, Texas Lung Injury Institute, The University of Texas Health Science Center at Tyler, Tyler, Texas, United States.
Ashoka Kumar BhagavathDepartment of Cellular and Molecular Biology, Texas Lung Injury Institute, The University of Texas Health Science Center at Tyler, Tyler, Texas, United States.
Akhila KongaraDepartment of Cellular and Molecular Biology, Texas Lung Injury Institute, The University of Texas Health Science Center at Tyler, Tyler, Texas, United States.
Hua TangDepartment of Cellular and Molecular Biology, Texas Lung Injury Institute, The University of Texas Health Science Center at Tyler, Tyler, Texas, United States.
Deborah E CitrinRadiation Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States.ORCID 0000-0002-4391-2734
Robert O WilliamsMolecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, Austin, Texas, United States.ORCID 0000-0003-4993-6427
Jay I PetersPulmonary Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States.ORCID 0000-0002-5230-1062
Sreerama ShettyDepartment of Cellular and Molecular Biology, Texas Lung Injury Institute, The University of Texas Health Science Center at Tyler, Tyler, Texas, United States.ORCID 0000-0002-1628-6029
Funding
Development, Formulation and Inhalational Delivery of a New Peptide for ILDR01HL151397 · NHLBI · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI SHETTY, SREERAMA · 2021 to 2024
$1.8M
Regulation of Silica-induced Lung Injury by Plasminogen Activator Inhibitor-1R21ES032506 · NIEHS · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI SHETTY, SREERAMA · 2022 to 2022
$404k
CSP7 inhibits toxicity of ionizing radiation to the lungR21CA282561 · NCI · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI Sreerama Shetty · 2025 to 2026
$398k
Role of p53 and PAI-1 in tobacco smoke exposure induced lung injuryR21ES025815 · NIEHS · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI SHETTY, SREERAMA · 2016 to 2017
Idiopathic pulmonary fibrosis (IPF) is a fatal disease characterized by progressive and irreversible loss of lung function. CSP7 exerts antifibrotic effects on fibrotic lung (myo)fibroblasts, which are the primary effector cells in progressive pulmonary fibrosis (PF) via restoring p53-microRNA-34a-feedback induction. However, p53-microRNA-34a's role in the antifibrotic effects of nintedanib and pirfenidone has not been explored. We compared the effects of oral-gavage-fed standard-of-care antifibrotic drugs, nintedanib or pirfenidone, with CSP7 administered by intraperitoneal injection or via airway by dry powder inhalation against bleomycin-induced PF using wild type, p53 flox (p53
Indexed as
Antifibrotic AgentsFibroblastsIdiopathic Pulmonary FibrosisIndolesLungMicroRNAsPyridonesTumor Suppressor Protein p53AnimalsBleomycinFeedback, PhysiologicalMaleMiceMice, Inbred C57BLMice, KnockoutAntifibrotic AgentsBleomycinIndolesMicroRNAsMIRN34a microRNA, mousenintedanibpirfenidonePyridonesTrp53 protein, mouseTumor Suppressor Protein p53CSP7fibrosisnintedanibp53-miR-34a feedbackpirfenidone
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
p53-miR-34a feedback in lung fibroblasts regulates antifibrotic effects of CSP7, nintedanib, and pirfenidone. · full record | OpenQuestion